Table 1 Ongoing clinical trials in breast cancer brain metastases
Tumor subtype | Treatment/target | Experimental arm | Control arm | Clinicaltrials.gov ID/phase |
|---|---|---|---|---|
All | Chemotherapy | Cabazitaxel | None | NCT02166658 Phase II |
TPI 287 | None | NCT01332630 Phase II | ||
ANG1005 | None | NCT02048059 Phase II | ||
ANG1005Â +Â trastuzumab (if HER2-positive) | None | NCT01480583 Phase II | ||
Liposomal cytarabine + high-dose methotrexate | None | NCT00992602 Phase II | ||
VEGF | Bevacizumab + carboplatin + trastuzumab (if HER2-positive) | None | NCT01004172 Phase II | |
Bevacizumab + etoposide + cisplatin followed by WBRT | WBRT alone | NCT02185352 Phase II | ||
Sorafenib + WBRT | None | NCT01724606 Phase I | ||
Cabozantinib + trastuzumab (if HER2-positive) | None | NCT02260531 Phase II | ||
Radiation | WBRTÂ +Â temozolamide | None | NCT02133677 Phase II | |
WBRT with hippocampal avoidance | Conventional WBRT | NCT01942980 Phase III | ||
WBRT + efaproxiral + oxygen | WBRT + oxygen | NCT00083304 Phase III | ||
HER2-positive | Chemotherapy | Cabazitaxel + lapatinib | None | NCT01934894 Phase II |
HER2 | Lapatinib + WBRT | WBRT alone | NCT01622868 Phase II | |
Neratinib ± capecitabine | None | NCT01494662 Phase II | ||
Afatinib ± vinorelbine | Investigator’s choice | NCT01441596 Phase II | ||
T-DM1Â +Â WBRT | None | NCT02135159 Phase I | ||
ARRY-380Â +Â trastuzumab | None | NCT01921335 Phase I | ||
mTOR | Everolimus + trastuzumab + vinorelbine | None | NCT01305941 Phase II | |
Everolimus + lapatinib + capecitabine | None | NCT01783756 Phase Ib/II | ||
PI3K | BKM120 + trastuzumab ± capecitabine | None | NCT01132664 Phase Ib/II | |
MET | Tesevatinib + trastuzumab | None | NCT02154529 Phase Ib/IIa | |
Radiation | PCI | None | NCT00916877 Phase I | |
PCI + taxane + trastuzumab | Taxane + trastuzumab | NCT00639366 Phase III | ||
SRSÂ +Â HER2 directed therapy | None | NCT01924351 Phase II | ||
Triple-negative | PI3K | BKM120Â +Â capecitabine | None | NCT02000882 Phase II |
PARP | Iniparib + irinotecan | None | NCT01173497 Phase II | |
Radiation | PCI | Observation | NCT02448576 Phase III | |
Hormone receptor-positive | CDK4/6 | Abemaciclib | None | NCT02308020 Phase II |